Scott G. Westphal, MD
Associate Professor, Division of Nephrology
Program Director, Nephrology Fellowship
402-559-9227
402-559-9504
Dr. Westphal's clinical focus is in the area of kidney and pancreas transplantation, where he is actively involved in caring for patients both before and after transplant. He also cares for patients with end-stage kidney disease receiving dialysis.
Dr. Westphal serves as the associate program director of the University of Nebraska Medical Center nephrology fellowship program and contributes to medical student education through multiple roles.
He participates in leadership and service roles within the American Society of Nephrology, the United Network of Organ Sharing, and the American Society of Transplantation.
Information
- Medical School: University of Iowa College of Medicine, 2010
- Internship: Duke University, 2011
- Residency: Internal Medicine, Duke University Medical Center, 2013
- Fellowship: Nephrology, Duke University Medical Center, 2015
Clinic Locations: Organ Transplant Center at Nebraska Medical Center; Grand Island Health Center; Shenandoah Medical Center
Hospital Appointments: Nebraska Medicine; Omaha VA Medical Center
Dr. Westphal's research interest includes improving access to kidney transplantation by studying the impact of organ allocation policies. His research particularly focuses on issues pertaining to multi-organ transplantation. Additional interests include the role of novel biomarkers in kidney transplantation, and improving kidney transplant outcomes.
Dr. Westphal's current research projects include:
- APOL1 Long Term Kidney Transplantation Outcomes Study (APOLLO)
Role: Principal Investigator
Sponsor: National Institute of Health (NIH)
Study Aim: Determine the impact of apolipoprotein L1 (APOL1) gene variants on outcomes in kidney transplant recipients and live kidney donors. - The PROspera Kidney Transplant ACTIVE Rejection Assessment registry (ProActive) study
Role: Principal Investigator
Sponsor: Natera
Study Aim: Evaluate the role of a blood-based donor-derived cell free DNA assay (Prospera) on
management and outcomes in kidney transplant recipients, as well as evaluate the test utility. - Trugraf Long-term Clinical Outcomes Study (TRULO)
Role: Principal Investigator
Sponsor: Transplant Genomics Inc.
Study Aim: Evaluate the impact of serial monitoring kidney transplant patients with both TruGraf® (a gene expression profile) and TRAC™ (donor-derived cell free DNA). - A Phase 3b, Open-Label, Safety, and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls (mRNA-1273-P304)
Role: Principal Investigator
Sponsor: Moderna Therapeutics
Study Aim: Evaluate the safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in kidney and liver transplant recipients.